Boehringer Ingelheim has started a proof-of-concept trial of a drug that could offer the first oral treatment for geographic atrophy (GA), a major cause of irreversible sight loss that affects ...

Astellas confirmed today that it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder geographic atrophy (GA), based on feedback from the EU regulator. It is a major ...

Top-line results announced in December showed Tadaraben reduced the growth rate of atrophy in Stargardt disease by 36% versus placebo, meeting the study's primary efficacy endpoint. PHOENIX trial ...

Key points A 4-year-old boy presented to our urgent ophthalmology clinic for photophobia and persistent eye rubbing. He had been born at 39 weeks via Cesarean delivery, without complications. Prenatal ...

A woman in her late 20s presented with a 5-year history of progressive fatigue and generalised weakness. Examination revealed ...

Arvinas (NASDAQ:ARVN) executives used the company’s fourth-quarter and full-year 2025 earnings call to outline a strategy ...

The next in our series of quick case-based quizzes in dermatology asks – what’s causing this facial rash involving darker ...

ADC Therapeutics SA , a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Tuesday, ...

TRYNGOLZA® generated $108 million in net product sales in 2025, the first year of launch –- Olezarsen sHTG launch ...